The Impact of Cross-Resistance Between Paclitaxel and Docetaxel for Metastatic Gastric Cancer

Publisher： Karger

E-ISSN： 2296-5262|35|4|176-183

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.35, Iss.4, 2012-03, pp. : 176-183

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Salvage Chemotherapy with Docetaxel and Epirubicin for Advanced/Metastatic Gastric Cancer

By  

Oncology, Vol. 73, Iss. 1-2, 2008-03 ,pp. : 2-8

Karger

Access to resources Recommend Favorite

Phase II Study of Docetaxel and Capecitabine in Patients with Metastatic or Recurrent Gastric Cancer

By  

Oncology, Vol. 68, Iss. 2-3, 2005-07 ,pp. : 190-195

Karger

Access to resources Recommend Favorite

Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials

By Qi Wei-Xiang   Shen Zan   Lin Feng   Sun Yuan-jue   Min Da-liu   Tang Li-Na   He Ai-Na   Yao Yang  

Current Medical Research and Opinion, Vol. 29, Iss. 2, 2013-02 ,pp. : 117-125

Informa Healthcare

Access to resources Recommend Favorite

Docetaxel Weekly with Metastatic Breast Cancer

By  

Oncology Research and Treatment, Vol. 30, Iss. 8-9, 2007-09 ,pp. : 407-408

Karger

Access to resources Recommend Favorite

Response Predictors of S-1, Cisplatin, and Docetaxel Combination Chemotherapy for Metastatic Gastric Cancer: Microarray Analysis of Whole Human Genes

By  

Oncology, Vol. 93, Iss. 2, 2017-05 ,pp. : 127-135

Karger

Access to resources Recommend Favorite